Study S001724

Effect of Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Statistical Analysis Plan (PDF)

Registration

Registration: NCT06191848
Acronym: STOP KNEE-OA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 352
Start: 2024-11-19
Primary completion: 2027-05
Lead sponsor: University of Melbourne
Conditions: Obesity; Knee Osteoarthritis; Osteoarthritis, Knee
Interventions: DRUG:Tirzepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percentage of patients who undergo knee replacement in the target joint [within 72 weeks of randomization]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002251	If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients? Ursini F, RMD open	2025	Nonrandomized study	PMID 40992788 DOI	cites ClinicalTrials.gov:NCT06191848; registry reference DERIVED:40992788